Day 1 - P.M. Live Cases with Presentations

Works at Montefiore Medical Center, New York, NY, US. Features in 40 videos on Wondr Medical. Azeem Latib generally speaks on Bioresorbable Vascular Scaffold (BVS), Drug Eluting Stents (DES), Intravascular Ultrasound (IVUS), Bifurcation, and Intracoronary Imaging.

Catalin Toma, MD, is an interventional cardiologist and is certified in cardiovascular disease and interventional cardiology by the American Board of Internal Medicine. He currently serves as director of interventional cardiology for the Heart and Vascular Institute and director of the Interventional Fellowship at UPMC. He is an assistant professor of medicine at the University of Pittsburgh School of Medicine. He received his medical degree from Grigore T. Popa University of Medicine and Pharmacy in Iasi, Romania. Following a post-doctoral fellowship at Johns Hopkins in Baltimore, he completed an internal medicine residency at St. Luke’s Roosevelt Hospital Center in New York City and a fellowship in cardiovascular disease and interventional cardiology at UPMC. Dr. Toma joined the UPMC Heart and Vascular Institute in 2007. He currently leads the Chronic Total Occlusion Program as well as the Pulmonary Vascular Interventional Program at UPMC Presbyterian Hospital. He is an integral part of the Structural Heart Program with interests in the aortic and tricuspid space. Additional interests include intracoronary imaging and mechanical circulatory support. Dr. Toma has had an extensive amount of publications and presentations over his career, has several invention patents, and serves as a clinical study leader at local and national levels.

Jai Khatri is a cardiologist at Cleveland Clinic, Cleveland, OH, USA.

An internationally recognized interventional cardiologist, Dr. Moses has performed more than 15,000 interventional procedures, authored over 600 publications, and served as lead investigator for numerous national and international clinical studies that have demonstrated the effectiveness and safety of coronary stent placement. In 2002, Dr. Moses was the lead investigator on a large clinical trial, the first in the U.S. that demonstrated the enormous benefit that led to FDA approval of the first drug-coated stent now used in the majority of interventional procedures in the U.S. Most recently in on the Executive Committee of PARTNER trial; they brought the first transcatheter aortic valve to clinical use in the U.S. He currently serves as Director of Interventional Cardiovascular Therapeutics at Columbia University Medical Center and as Director of Advanced Cardiac Interventions at St Francis Hospital and Heart Center in Roslyn, NY. He is also a pioneer in developing approaches involving minimally invasive surgery, angioplasty, gene therapy, novel imaging technologies and various support devices that allow for wider application of interventional cardiovascular procedures.

Dr. Rhian E. Davies is currently practicing at WellSpan Health in York Pa. She completed her Internal Medicine Residency and General Cardiology Fellowship at Penn State Milton S. Hershey Medical Center in 2018. This w followed by an interventional year at Warren Alpert Medical School of Brown University. She subsequently completed an Advanced Interventional Cardiology Fellowship at the University of Washington where she focused on CTO PCI. Her clinical interest include radial access, mechanical circulatory support, complex coronary and CTO procedures.

Dr. Rogers is an interventional cardiologist and scientific lead for the MedStar Heart & Vascular Institute Structural Heart Disease program. He has a special interest in all aspects of minimally invasive treatment of structural heart disease, including Transcatheter Aortic Valve Replacement (TAVR), Transcaval access, Transcatheter Electrosurgery (LAMPOON and BASILICA techniques), para-valvular leak closure, percutaneous treatment of mitral valve regurgitation including Mitraclip and Transcatheter Mitral Valve Replacement (TMVR), LAA occluder, percutaneous pulmonary and tricuspid valve interventions, and cerebral protection devices for TAVR.